Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results View Full Press Release Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results